Anna E Coghill1, Meredith S Shiels, Randi K Rycroft, Glenn Copeland, Jack L Finch, Anne M Hakenewerth, Karen S Pawlish, Eric A Engels. 1. aDivision of Cancer Epidemiology and Genetics, National Cancer InstitutebColorado Central Cancer Registry, Colorado Department of Public Health and Environment, Denver, ColoradocMichigan Cancer Surveillance Program, Michigan Stage Cancer RegistrydCommunicable Disease Branch, North Carolina Division of Public HealtheNew Jersey State Cancer Registry, New Jersey Department of Health, Trenton, New Jersey, USA.
Abstract
OBJECTIVE: Squamous cell carcinoma (SCC) of the rectum is rare, but as with anal cancer, risk may be increased among immunosuppressed individuals. We assessed risk of rectal SCC in HIV-infected people. DESIGN: Population-based registry. METHODS: We utilized the HIV/AIDS Cancer Match, a linkage of US HIV and cancer registries (1991-2010), to ascertain cases of anal SCC, rectal SCC, rectal non-SCC, and colon non-SCC. We compared risk in HIV-infected persons with the general population using standardized incidence ratios (SIRs) and evaluated risk factors using Poisson regression. We reviewed cancer registry case notes to confirm site and histology for a subset of cases. RESULTS: HIV-infected persons had an excess risk of rectal SCC compared with the general population (SIR = 28.9; 95% CI 23.2-35.6), similar to the increase for anal SCC (SIR = 37.3). Excess rectal SCC risk was most pronounced among HIV-infected MSM (SIR = 61.2). Risk was not elevated for rectal non-SCC (SIR = 0.88) or colon non-SCC (SIR = 0.63). Individuals diagnosed with AIDS had higher rectal SCC rates than those with HIV-only (incidence rate ratio = 1.92; 95% CI 1.08-3.42). Based on available information, one-third of rectal SCCs were determined to be misclassified anal cancer. CONCLUSION: HIV-infected individuals, especially with advanced immunosuppression, appear to have substantially elevated risk for rectal SCC. As for anal SCC, rectal SCC risk was highest in MSM, pointing to involvement of a sexually transmitted infection such as human papillomavirus. Site misclassification was present, and detailed information on tumour location is needed to prove that rectal SCC is a distinct entity.
OBJECTIVE:Squamous cell carcinoma (SCC) of the rectum is rare, but as with anal cancer, risk may be increased among immunosuppressed individuals. We assessed risk of rectal SCC in HIV-infected people. DESIGN: Population-based registry. METHODS: We utilized the HIV/AIDS Cancer Match, a linkage of US HIV and cancer registries (1991-2010), to ascertain cases of anal SCC, rectal SCC, rectal non-SCC, and colon non-SCC. We compared risk in HIV-infectedpersons with the general population using standardized incidence ratios (SIRs) and evaluated risk factors using Poisson regression. We reviewed cancer registry case notes to confirm site and histology for a subset of cases. RESULTS:HIV-infectedpersons had an excess risk of rectal SCC compared with the general population (SIR = 28.9; 95% CI 23.2-35.6), similar to the increase for anal SCC (SIR = 37.3). Excess rectal SCC risk was most pronounced among HIV-infected MSM (SIR = 61.2). Risk was not elevated for rectal non-SCC (SIR = 0.88) or colon non-SCC (SIR = 0.63). Individuals diagnosed with AIDS had higher rectal SCC rates than those with HIV-only (incidence rate ratio = 1.92; 95% CI 1.08-3.42). Based on available information, one-third of rectal SCCs were determined to be misclassified anal cancer. CONCLUSION:HIV-infected individuals, especially with advanced immunosuppression, appear to have substantially elevated risk for rectal SCC. As for anal SCC, rectal SCC risk was highest in MSM, pointing to involvement of a sexually transmitted infection such as human papillomavirus. Site misclassification was present, and detailed information on tumour location is needed to prove that rectal SCC is a distinct entity.
Authors: M Frisch; B Glimelius; A J van den Brule; J Wohlfahrt; C J Meijer; J M Walboomers; S Goldman; C Svensson; H O Adami; M Melbye Journal: N Engl J Med Date: 1997-11-06 Impact factor: 91.245
Authors: Eric A Engels; Ruth M Pfeiffer; James J Goedert; Phillip Virgo; Timothy S McNeel; Steven M Scoppa; Robert J Biggar Journal: AIDS Date: 2006-08-01 Impact factor: 4.177
Authors: Meredith S Shiels; Aimée R Kreimer; Anna E Coghill; Teresa M Darragh; Susan S Devesa Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-07-29 Impact factor: 4.254
Authors: Eric A Engels; Ruth M Pfeiffer; Joseph F Fraumeni; Bertram L Kasiske; Ajay K Israni; Jon J Snyder; Robert A Wolfe; Nathan P Goodrich; A Rana Bayakly; Christina A Clarke; Glenn Copeland; Jack L Finch; Mary Lou Fleissner; Marc T Goodman; Amy Kahn; Lori Koch; Charles F Lynch; Margaret M Madeleine; Karen Pawlish; Chandrika Rao; Melanie A Williams; David Castenson; Michael Curry; Ruth Parsons; Gregory Fant; Monica Lin Journal: JAMA Date: 2011-11-02 Impact factor: 157.335
Authors: Jacqueline Mix; Mona Saraiya; Charles F Lynch; Trevor D Thompson; April Greek; Thomas C Tucker; Edward S Peters; Troy D Querec; Elizabeth R Unger Journal: J Registry Manag Date: 2019
Authors: Anna E Coghill; Eric A Engels; Maria J Schymura; Parag Mahale; Meredith S Shiels Journal: J Natl Cancer Inst Date: 2018-09-01 Impact factor: 13.506
Authors: Anna E Coghill; Andrew M Bellizzi; Charles F Lynch; Meredith S Shiels; Freda R Selk; Maura Gillison; Brenda Y Hernandez; Owen T M Chan; Eric A Engels Journal: Clin Gastroenterol Hepatol Date: 2018-11-15 Impact factor: 11.382
Authors: Hilda Razzaghi; Mona Saraiya; Trevor D Thompson; S Jane Henley; Laura Viens; Reda Wilson Journal: Cancer Date: 2017-11-06 Impact factor: 6.860